These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 22928661

  • 1. Cyclin-dependent kinase modulators and cancer therapy.
    Gallorini M, Cataldi A, di Giacomo V.
    BioDrugs; 2012 Dec 01; 26(6):377-91. PubMed ID: 22928661
    [Abstract] [Full Text] [Related]

  • 2. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R.
    Pharmacol Res; 2016 May 01; 107():249-275. PubMed ID: 26995305
    [Abstract] [Full Text] [Related]

  • 3. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R.
    Pharmacol Res; 2019 Jan 01; 139():471-488. PubMed ID: 30508677
    [Abstract] [Full Text] [Related]

  • 4. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Blachly JS, Byrd JC, Grever M.
    Semin Oncol; 2016 Apr 01; 43(2):265-73. PubMed ID: 27040705
    [Abstract] [Full Text] [Related]

  • 5. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
    Chohan TA, Qayyum A, Rehman K, Tariq M, Akash MSH.
    Biomed Pharmacother; 2018 Nov 01; 107():1326-1341. PubMed ID: 30257348
    [Abstract] [Full Text] [Related]

  • 6. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
    Klein MA.
    Adv Protein Chem Struct Biol; 2020 Nov 01; 121():115-141. PubMed ID: 32312419
    [Abstract] [Full Text] [Related]

  • 7. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L, Siu KT, Raje N.
    Semin Oncol; 2015 Dec 01; 42(6):788-800. PubMed ID: 26615126
    [Abstract] [Full Text] [Related]

  • 8. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
    Abate AA, Pentimalli F, Esposito L, Giordano A.
    Expert Opin Investig Drugs; 2013 Jul 01; 22(7):895-906. PubMed ID: 23735075
    [Abstract] [Full Text] [Related]

  • 9. Cyclins and related kinases in cancer cells.
    Malumbres M.
    J BUON; 2007 Sep 01; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [Abstract] [Full Text] [Related]

  • 10. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
    Wesierska-Gadek J, Schmid G.
    Expert Opin Investig Drugs; 2006 Jan 01; 15(1):23-38. PubMed ID: 16370931
    [Abstract] [Full Text] [Related]

  • 11. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
    Bruyère C, Meijer L.
    Curr Opin Cell Biol; 2013 Dec 01; 25(6):772-9. PubMed ID: 24011867
    [Abstract] [Full Text] [Related]

  • 12. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy.
    Bury M, Le Calvé B, Ferbeyre G, Blank V, Lessard F.
    Trends Cell Biol; 2021 May 01; 31(5):331-344. PubMed ID: 33676803
    [Abstract] [Full Text] [Related]

  • 13. Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
    Qin A, Reddy HG, Weinberg FD, Kalemkerian GP.
    Expert Opin Pharmacother; 2020 Jun 01; 21(8):941-952. PubMed ID: 32164461
    [Abstract] [Full Text] [Related]

  • 14. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM.
    Cancer Chemother Pharmacol; 2003 Jul 01; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [Abstract] [Full Text] [Related]

  • 15. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
    Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, Yu M, Lin J, Cui Q.
    Int J Mol Sci; 2020 Mar 13; 21(6):. PubMed ID: 32183020
    [Abstract] [Full Text] [Related]

  • 16. Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
    Senderowicz AM.
    Prog Drug Res; 2005 Mar 13; 63():183-206. PubMed ID: 16265881
    [Abstract] [Full Text] [Related]

  • 17. Early development of cyclin dependent kinase modulators.
    Roy KK, Sausville EA.
    Curr Pharm Des; 2001 Nov 13; 7(16):1669-87. PubMed ID: 11562305
    [Abstract] [Full Text] [Related]

  • 18. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C, Novellino E, Chilin A, Lavecchia A, Marzaro G.
    Expert Opin Investig Drugs; 2016 Oct 13; 25(10):1215-30. PubMed ID: 27606939
    [Abstract] [Full Text] [Related]

  • 19. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.
    Vermeulen K, Van Bockstaele DR, Berneman ZN.
    Cell Prolif; 2003 Jun 13; 36(3):131-49. PubMed ID: 12814430
    [Abstract] [Full Text] [Related]

  • 20. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J, Chamrád I, Kryštof V.
    Future Med Chem; 2009 Dec 13; 1(9):1561-81. PubMed ID: 21425979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.